Glatiramer acetate injection is a treatment for multiple sclerosis. ScinoPharm Taiwan pointed out that since its approval in 1996, glatiramer acetate has been recognized as one of the most challenging ...

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...

If an optional autoinjector is used for administration, patients should ensure the device is compatible for use with their specific glatiramer acetate product. The labels for glatiramer acetate ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of ...

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

The FDA is warning healthcare professionals about compatibility issues between autoinjectors and glatiramer acetate injections, which are approved to treat relapsing forms of multiple sclerosis. If ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its ...

(MENAFN- GlobeNewsWire - Nasdaq) NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on ...

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be ...